Výsledky vyhledávání - "Oksana Mason"

Budget impact of lasmiditan for the acute treatment of migraine in the United States

Autor: Gerhardt Pohl, Oksana Mason, Sandra Milev, Li Shen Loo, Nancy Njuguna, Ariel Sun

Publikováno v: Journal of Managed Care & Specialty Pharmacy. 27:1714-1723

BACKGROUND: Three novel acute treatments for migraine-lasmiditan, ubrogepant, and rimegepant-were approved by the FDA in 2019 and 2020 for adults with migraine with and without aura. American Headache Society guidance recommends that these novel acut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4c7eb60cd1b9f6edfb1ad9e3ce5f01d
https://doi.org/10.18553/jmcp.2021.27.12.1714

Zobrazit plný text záznamu

Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database

Autor: Chi-Chang Chen, Shonda A. Foster, Wenyu Ye, Catherine B McGuiness, Timothy R Smith, Shivang Joshi, Rolin L Wade, Oksana Mason, Paula C. Morrow, Yao Ding

Publikováno v: Journal of Medical Economics. 23:1356-1364

To evaluate the prevalence and risk factors of migraine progression and to assess the incremental burden of migraine progression on healthcare systems.Adult patients were required to have a migraine diagnosis in IQVIA's US adjudicated claims database

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b18ad5aecae5d15496efa7d0284950
https://doi.org/10.1080/13696998.2020.1814790

Zobrazit plný text záznamu

Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology

Autor: Lisa M. Hess, Alan Brnabic, Pablo Lee, Oksana Mason, Scott S. Barker

Publikováno v: Journal of Cancer

Introduction: With a gap in a full understanding of the mechanisms by which survival is extended for patients with cancer who are treated with novel biologic and targeted agents, there is the risk that discordant progression-free and overall survival

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e34eaa9c668046ef8b8037fc1a17134d
http://europepmc.org/articles/PMC6636299

Zobrazit plný text záznamu

Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study

Autor: Wenyu Ye, Karen Samaan, Dena H. Jaffe, Oksana Mason, John C. Rowland, Shonda A. Foster, Bridget L. Balkaran, M. Janelle Cambron-Mellott

To characterize burden of migraine in prevention-eligible patients compared with prevention non-eligible patients in the United States (US). Receipt of preventive therapy was also examined among prevention-eligible patients. This retrospective study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8588ae9ce0db5cfc9ccee610b78e900b

Zobrazit plný text záznamu

Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes

Autor: Janet H. Ford, Margaret Hoyt, Wenyu Ye, Shonda A. Foster, Oksana Mason

This study compared all-cause direct cost and healthcare resource utilization (HCRU) among preventive migraine medication (PMM)-naïve patients and patients with up to 3 PMM category switches before initiating calcitonin gene-related peptide (CGRP) m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7337578d76e6408f59d3ebc4f473b79

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání